Winton Group’s Cymabay Therapeutics CBAY Stock Holding History

Winton Group’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-17,659	Closed	-$64K	–	1486
2021 Q3	$64K	Buy	+17,659	New	+$69.6K	﹤0.01%	1303
2020 Q3	–	Sell	-58,754	Closed	-$205K	–	1646
2020 Q2	$205K	Buy	+58,754	New	+$170K	0.01%	1355
2020 Q1	–	Sell	-199,381	Closed	-$391K	–	1577
2019 Q4	$391K	Buy	+199,381	New	+$749K	0.01%	1304
2019 Q1	–	Sell	-27,793	Closed	-$219K	–	1212
2018 Q4	$219K	Buy	27,793 +257	+0.9%	+$2.45K	﹤0.01%	779
2018 Q3	$305K	Buy	+27,536	New	+$342K	0.01%	812

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Winton Group's CBAY Position: Q4 2021 in Review

Winton Group sold out of Cymabay Therapeutics (CBAY) in Q4 2021, closing a stake of 17,659 shares — an estimated $64K sold.

Winton Group first reported a position in CBAY in Q3 2018 and held it in 5 quarters. The position peaked at $391K in Q4 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2021.

Winton Group reported no remaining Cymabay Therapeutics position as of Q4 2021 after selling out during the quarter.
Winton Group sold 17,659 Cymabay Therapeutics shares in Q4 2021, an estimated $64K.
Winton Group first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 5 quarters.
Winton Group's Cymabay Therapeutics position peaked at $391K in Q4 2019.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.